id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2019-D-5473-0002,FDA,FDA-2019-D-5473,"Promotional Labeling and Advertising Considerations for Prescription Biological Reference and Biosimilar Products Questions and Answers
Guidance for Industry",Other,Guidance,2020-02-04T05:00:00Z,2020,2,2020-02-04T05:00:00Z,2020-04-07T03:59:59Z,2024-04-25T13:29:55Z,,0,0,0900006484325d68
FDA-2019-D-5473-0001,FDA,FDA-2019-D-5473,"Promotional Labeling and Advertising Considerations for Prescription
Biological Reference and Biosimilar Products—Questions and Answers;
Draft Guidance for Industry; Availability",Notice,Notice of Availability,2020-02-04T05:00:00Z,2020,2,2020-02-04T05:00:00Z,2020-04-07T03:59:59Z,2020-02-23T21:50:39Z,2020-02100,0,0,0900006484325636